SecBot SecBot
Biotech Drug Report Generated Nov 14, 2026

GPC-100

XCUR·EXICURE, INC.
MIXED
Drug Impact Rating4/10
Trial phase
Phase 2
Time to market
No timeline is estimable. The drug is still at Phase 2 with no announced Phase 3 plan under Exicure. The program is being sold to GPCRT Inc., making any go-to-market timeline dependent on the buyer's development strategy.
Why 4/10
The Phase 2 readout is already in the past (ASH December 2025). No pivotal Phase 3 trial or regulatory filing is scheduled. The next hard catalyst is the asset sale closing on November 30, 2026, but M&A/corporate events are not counted as drug-development catalysts under the rubric, capping the impact score at 4.
Actionable Insight MIXED

Watch the November 16, 2026 interim payment deadline (KRW 2.0 billion) as a sign of deal commitment from GPCRT Inc., and the November 30, 2026 expected closing. If the deal closes, Exicure will have ~$4.8M cash but no operating assets. If it fails, Exicure faces a severe liquidity crunch with no pipeline and an active Nasdaq delisting notice.

Price Chart

Loading chart...

Executive Summary

GPC-100 (burixafor) is a Phase 2 small-molecule CXCR4 antagonist for stem cell mobilization in multiple myeloma patients. A Phase 2 trial (NCT05561751, n=30) completed in October 2025, and positive topline results showing nearly 90% cell mobilization were presented at the December 2025 ASH meeting. However, developer Exicure (XCUR) ran out of cash and on November 10, 2026 agreed to sell all GPC-100 program assets to South Korea's GPCRT Inc. for KRW 6.5 billion (~$4.8M), with closing targeted for November 30, 2026. Exicure has no other pipeline assets and faces a Nasdaq delisting notice, making this essentially a single-asset going-concern story that is now being wound down.

How It Works

GPC-100 (burixafor) is a small molecule that blocks the CXCR4 receptor, a protein on the surface of certain blood cells. By blocking CXCR4, the drug helps release stem cells from the bone marrow into the bloodstream, where they can be collected for stem cell transplants. It was tested as a way to mobilize stem cells in multiple myeloma patients preparing for an autologous stem cell transplant.

Trial Status

A Phase 2 trial (NCT05561751) testing GPC-100 plus propranolol with or without G-CSF for stem cell mobiliztion in 30 multiple myeloma patients is COMPLETED (primary completion September 2025, actual completion October 2025). Topline positive results were preseted at the Decmber 2025 ASH Annul Meeting, showing nearly 90% blood cell mobilization in patients. No Phase 3 trial has been started, and the program is now being sold.

The Two-Sided Case

▲ Bull Case3
GPC-100 (burixafor) showed positive Phase 2 topline data at the December 2025 ASH meeting, with nearly 90% stem cell mobilization in multiple myeloma patients, suggesting meaningful clinical activity.
The KRW 6.5 billion (~$4.8M) asset sale to GPCRT Inc. provides a cash infusion worth roughly 80% of Exicure's market cap, potentially extending the company's runway.
The drug's CXCR4 mechanism is a validated target for stem cell mobilization, similar to approved drugs like plerixafor (Mozobil).
▼ Bear Case4
Exicure is selling the GPC-100 program because it cannot fund further development; the company had only $3.7M in cash as of early 2026 and received a Nasdaq delisting notice in September 2026.
After the sale closes, Exicure will have no active drug pipeline, raising going-concern and reverse-merger-or-liquidation risk.
The company retains ~$1.4M in pre-September 2026 program liabilities (unpaid CRO fees of $644K and sublease obligations of $783K), and the deal could still fail to close.
Analyst consensus is sharply negative: 0 Buy, 3 Hold, 1 Sell, 2 Strong Sell, with no price targets set.

Upcoming Catalysts

  • November 16, 2026: interim KRW 2.0 billion payment due from GPCRT Inc.
  • November 30, 2026: expected closing of asset sale to GPCRT Inc. for KRW 6.5 billion (~$4.8M)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

EXICURE, INC. 8-K XCUR ·Originating report

Sources · 7

Hover a chip for the title
1 sec.gov2 benzinga.com3 fiercebiotech.com4 msn.com5 streetinsider.com6 tipranks.com7 ad-hoc-news.de